UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Assess which Dividend Aristocrats ETF offers the lowest expenses while maintaining solid diversification and dividend potential for your portfolio.
27,511 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
American Express has carved a niche by serving high-spending clients with premium perks. This article explores whethe...
ASML is set to report Q2 results on July 15, 2026, with investors eyeing an reaffirmed or higher FY2026 revenue targe...
Is a recession priced into market? This guide breaks down what pricing in expectations really means, the data to watc...
When high-profile investors tilt toward value, curious readers take note. This piece breaks down why billionaire Bill...
America’s energy chart has flipped from import-reliant to resilient. This report explains how something’s different a...
CrowdStrike stock absolutely hammered this week, yet the dip isn’t a clear buy signal. I break down the risks, the gr...
Pinterest has shown strong quarterly results, yet the stock moves on mixed signals. This guide breaks down the what's...
Betterware de Mexico appears to be trading at a discount despite a growth plan centered on Latin America expansion an...
Apple may be eyeing a breakthrough to reduce on-device memory needs, a move that could shake Micron and the broader m...
A market dip in the chip sector created a rare buying opportunity. This guide features three thoughtful picks to own ...
Oracle stock faces a pivotal moment as management doubles down on AI infrastructure while financing plans raise dilut...